Milefchik Rand Medical Group is categorized under Infectious Disease Specialists in Torrance, CA and active since 2002.
Milefchik Rand Medical Group was established in 2002, and today employs 1 to 4, earning $2.500.000 to $4.999.999 per year. This is a Infectious Disease Specialists business, which does work in the B2C market, and is classified as a Infectious Disease Specialists, under code number by the NAICS.
If you are seeking more information, feel free to contact JUDY LANDRUM at the company’s single location by writing to 2841 Lomita Boulevard # 135, Torrance, California CA 90505 or by phoning (310) 784-6954. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Milefchik Rand Medical Group |
| Contact Person: | JUDY LANDRUM |
| Address: | 2841 Lomita Boulevard # 135, Torrance, California 90505 |
| Phone Number: | (310) 784-6954 |
| Annual Revenue (USD): | $2.500.000 to $4.999.999 |
| Founded: | 2002 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Infectious Disease Specialists |
| Share This Business: |
Milefchik Rand Medical Group was started in 2002 to provide professional Infectious Disease Specialists under the SIC code and NAICS code . Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $2.500.000 to $4.999.999 per annum.
Feel free to contact JUDY LANDRUM for inquiries that concern Milefchik Rand Medical Group by calling the company number (310) 784-6954, as your correspondence is most welcome. Additionally, the physical location of the single location of Milefchik Rand Medical Group can be found at the coordinates 33.813300,-118.345330 as well as the street address 2841 Lomita Boulevard # 135 in Torrance, California 90505.
For its online presence, you may visit Milefchik Rand Medical Group’s website at and engage with its social media outlets through on Twitter and on Facebook.